|
| NB: The information displayed below does not replace the protocol. The latest protocol version should always be consulted before making clinical decisions. |
|
RituxiCAN-C4
|
|
Randomised controlled trial of anti-CD20 in patients with C4d+ chronic allograft nephropathy
|
|
|
Topic
|
|
Inflammatory and Immune
|
|
Portfolio Eligibility
|
|
Funded by UKCRC partner
|
|
|
ISRCTN
|
|
|
EudraCT
|
2006-002330-38
|
|
MREC N° |
06/Q0406/119
|
|
UKCRN ID |
6759
|
|
WHO ID
|
|
|
|
|
Study Type |
Both
|
|
Design Type |
Not specified, Treatment, Not specified
|
|
Disease(s) |
Immunology and inflammation
|
|
Phase |
IV
|
|
|
Current Status
| Open |
| Closure Date | 30/11/2012 |
|
Sample Size
| 120 |
| Accrual to Date |
 19% |
|
|
|
Geographical Scope
| UK Multi-Centre |
|
Lead Country
| England |
|
Open to new sites
| Yes, within lead country only |
|
|
Main Inclusion Criteria
|
|
Unknown
|
|
|
Main Exclusion Criteria
|
|
Unknown
|
|
|
Chief Investigator(s)
|
| Prof Anthony Dorling |
|
|
Further details, please contact
|
Prof Anthony Dorling
Imperial College London
Department of Immunology
Tel: 020 7188 5880
anthony.dorling@kcl.ac.uk
|
|
|
Funder(s) |
Medical Research Council
Roche Ltd
|
|
Sponsor(s) |
|
|
|
|